Home Newsfeeds RBC Capital Upgrades Canfor Pulp Products to Outperform, Raises Price Target to C$8

RBC Capital Upgrades Canfor Pulp Products to Outperform, Raises Price Target to C$8

RBC Capital analyst Paul Quinn upgrades Canfor Pulp Products (TSX:CFX) from Sector Perform to Outperform and raises the price target from C$6 to C$8.

byBenzinga Newsdesk

July 18, 2022

1 minute read

RBC Capital analyst Paul Quinn upgrades Canfor Pulp Products (TSX:CFX) from Sector Perform to Outperform and raises the price target from C$6 to C$8.

Can Cannabis Treat Severe Forms Of Epilepsy? New Medicine Sparks Hope As Colombia’s Weed Industry Goes Global

By Nicolas Jose Rodriguez

February 14, 12:21 PM

Clever Leaves Holdings Inc.

AVCNF

Uber, Whirlpool And An Oil Giant Analysts Love: CNBC’s ‘Final Trades’

By Priya Nigam

September 1, 9:25 AM

On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management said Whirlpool Corporation (NYSE: WHR) has a

CVX

Vital Farms Q4 EPS $0.04, Inline, Sales $110.10M Beat $100.29M Estimate

By Benzinga Newsdesk

March 9, 8:20 AM

Vital Farms (NASDAQ:VITL) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 144.44 percent increase over losses of $(0.09) per share from the same period last year. The

VITL

Theseus Pharmaceuticals Nominates THE-349, A Fourth-Generation EGFR Inhibitor Development Candidate In Non-Small Cell Lung Cancer

By Benzinga Newsdesk

October 3, 7:04 AM

THE-349 is a fourth-generation, potent and selective, small molecule designed to inhibit all major classes of EGFR activating and resistance mutations Preclinical data to be presented at the 34th EORTC-NCI-AACR

THRX

RBC Capital Upgrades Canfor Pulp Products to Outperform, Raises Price Target to C$8

Related Posts

Can Cannabis Treat Severe Forms Of Epilepsy? New Medicine Sparks Hope As Colombia’s Weed Industry Goes Global

Uber, Whirlpool And An Oil Giant Analysts Love: CNBC’s ‘Final Trades’

Vital Farms Q4 EPS $0.04, Inline, Sales $110.10M Beat $100.29M Estimate

Theseus Pharmaceuticals Nominates THE-349, A Fourth-Generation EGFR Inhibitor Development Candidate In Non-Small Cell Lung Cancer